Fresenius Kabi Oncology Ltd Directors Report

Dear Shareholders,

The Board of Directors is pleased to present the report on the Companys business and operations for the financial year ended March 31, 2025.

FINANCIAL PERFORMANCE

Key aspects of Companys financial performance for the financial year ended March 31, 2025 are summarized below:

(INR in Lakh)

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Turnover (including other income)	84,825.71	81,491.31
Profit/(Loss) before Tax and Exceptional Items	10,118.79	7,240.70
Extraordinary Items	-	-
Profit/ (Loss) before tax	10,118.79	7,240.70
Less: Provision for taxation
(i) Current tax expenses	(526.20)	-
(ii) Deferred tax charge	(2,079.56)	(1,820.63)
Profit/(Loss) after tax	7,513.03	5,420.07
Other comprehensive Income	1.04	33.25
Other (Total) comprehensive income/loss for the year	7,514.07	5,453.32
Add: Balance of Profit/ (Loss) & Other comprehensive Income/ (Loss) brought forward from previous year	(51,343.11)	(56,796.43)
Appropriation to:
General Reserve	-	-
Balance carried over to the Balance Sheet	(43,829.04)	(51,343.11)

DIVIDEND

In view of the accumulated losses incurred by the Company, the Board is unable to recommend any dividend for the financial year 2024-25.

BUSINESS PERFORMANCE AND OPERATIONS

The management is committed to implement industry best practices at all levels. The Managements channelized efforts and strategies in this direction have resulted in sustained growth in revenues and profits after tax as compared to the previous financial year. The bright part was that the Companys operations are turning in the right direction, gradually and steadily during the year.

Financial snapshots:

> Revenue increased to INR 84,825.71 lakhs in FY 2024-25 from INR 81,491.31 lakhs in FY 2023-24, an increase of INR 3,334.40 lakhs (4.09%).

> Profit before tax increased to INR 10,118.79 lakhs in FY 2024-25 as compared to INR 7,240.70 lakhs in FY 2023-24.

GLOBAL & DOMESTIC INDUSTRY OUTLOOK AND TRENDS IN ONCOLOGY Global Trends in Oncology - 2025:

Cancer treatment has evolved significantly in recent years, offering new hope and improved outcomes for patients worldwide. As we enter 2025, cutting-edge therapies and technological advancements continue to transform the landscape of oncology.

One of the most significant breakthroughs in cancer treatment is the advancement of precision medicine. This approach tailors treatment based on an individuals genetic profile, ensuring therapies are more effective with fewer side effects. Genomic Testing identifies genetic mutations in tumors helping doctors select targeted therapies. Further in the Biomarker-Driven Therapies, specific biomarkers guide treatment decisions, improving success rates and minimizing unnecessary treatments.

Radiation therapy remains a cornerstone of cancer treatment, and new technologies are making it more precise and effective. The Adaptive Radiation Therapy (ART), uses real-time imaging to adjust radiation doses, improving accuracy and reducing side effects.

Immunotherapy, which enhances the bodys immune system to fight cancer, has also continued to progress. Next-Generation Checkpoint Inhibitors help the immune system recognize and attack cancer cells more effectively. CAR-T Cell Therapy Expansions, originally used for blood cancers, is now showing promise for solid tumors, as well.

Surgical advancements are making cancer treatment less invasive, leading to quicker recoveries and better patient outcomes. The Robotic-Assisted Surgery enhances precision and reduces recovery time for complex cancer surgeries. Laparoscopic and Endoscopic Techniques are allowing smaller incisions and less post-operative pain.

New drug developments continue to push the boundaries of effective cancer treatment. Antibody- Drug Conjugates (ADCs), deliver targeted chemotherapy directly to cancer cells, reducing toxicity.

The Oncology Market was valued at USD 320.3 billion in 2024, and is projected to reach USD 866.1 billion by 2034, rising at a CAGR of 10.8%.

The rising incidence of cancer worldwide remains the key driver of market expansion, prompting increased demand for advanced treatments and diagnostics. As cancer cases surge across all age groups, healthcare systems are intensifying efforts to improve patient outcomes through novel therapies, precision medicine, and technological advancements in diagnostics. The oncology sector continues to witness significant investment from pharmaceutical and biotechnology firms, leading to groundbreaking innovations in immunotherapies, targeted therapies, and early detection methods.

The growing focus on personalized medicine, driven by genomics and biomarker research, is transforming the landscape of cancer treatment. Government initiatives, rising healthcare expenditures, and increased awareness campaigns further contribute to market growth, emphasizing the urgent need for better accessibility to cutting-edge cancer therapies and diagnostics.

Domestic Trends in Oncology - 2025

One of the key trends in the Indian Oncology Drugs market is the increasing adoption of targeted therapies. These drugs are designed to target specific molecules or pathways involved in the growth and spread of cancer cells and have been shown to be more effective and less toxic than traditional chemotherapy drugs. Another trend in the market is the growing importance of biosimilars. Biosimilars are becoming increasingly popular in India due to their lower cost and greater accessibility compared to the original biologic drugs.

The oncology market in India is forecasted to grow by USD 2.01 billion during 2024-2029, accelerating at a CAGR of 19.8%.

According to various reports, the burden of cancer in India is projected to increase, with an estimated 1.6 million new cases and 700,000 deaths by 2025. This trend is driven by factors such as population growth, urbanization, and lifestyle changes. In response to this growing demand, there is a surge in R&D activities aimed at developing advanced diagnostic devices and innovative treatments. For instance, Indian institutions and startups are investing in research and development of affordable cancer diagnostics, making early detection more accessible and affordable.

In India, oncology market participants are investing substantially in research and development to create advanced diagnostic devices for cancer detection and treatment. One innovative approach is the application of gold nanoparticles in cancer diagnostics. This technique combines a therapeutic agent, a diagnostic agent, and gold nanoparticles. The resulting combination facilitates effective monitoring of target tumors and offers valuable insights into the impact of cancer drugs on tumors.

This strategy will foster the development of novel theragnostic combined therapies, leading to increased demand and utilization of cancer diagnostic devices. This investment in research and development is a strategic move to address the growing need for effective cancer treatments and diagnostics.

Key updates on the Companys plants

Initiatives towards upgradation of plant processes and cost reduction were undertaken at both the plants during the year under review, which included:

Kalyani Plant:

1. Capacity increased for:

- Carboplatin from 750 Kg/month to 1200 Kg/month;

- Docetaxel from 50 Kg/month to 90 Kg/month;

- Sugammadex plant capacity increased from 500 Kg/month to 1200 Kg/month;

2. New Product validation - Cisplatin - filed for EU & Phm market;

3. Facility upgradation for corrosive material storage area;

4. Biogas project Commissioned;

5. Automation of Warehouse AHU for temperature control with VFD;

6. Batch sizes scale up for:

- Sugammadex by 1.2 T (Input from 39 Kg to 48 Kg)

- Gemciatbine by 1.5 T (Input from 27 Kg to 40 Kg)

- Busulfan by 1.5 T (Input from 0.6 Kg to 0.9 Kg)

7. Implementation of Digitalization Projects like Data logger for online recoding of the process parameters, Barcode for material management, Solvent distribution System upgradation;

8. RO EDI - RO+EDI sanitization hot water used in boiler feed water tank to save water & fuel;

9. Zero Accidents and No Manhour loss;

10. Energy saving initiatives like replacement of Pumps, use of alternate fuels in Boiler.

Baddi Plant:

1. Record 7.6 Million vials were filled in 2024 owing to many productivity improvement projects (46% increase in B2B batches & 44% decrease in split batches vs 2023);

2. 2^nd highest production volume achieved in a month of November 2024 i.e. 9.18 lac vials;

3. Spot Sales of 195,000 vials accommodated with great versatility and prompt support of PU, Baddi;

4. Surpassed FC3-2024 target by 161K Euro (12,950 K EUR release vs 12,789 K EUR);

5. 84.7% volume of Europe were shipped by SEA route despite Global geopolitical challenges in logistics movement;

6. 73.3% PU Service level-maintained YTD 2024 at par with previous trend despite growing market demand and shutdowns at Line-I & Line-II to fulfil site compliance;

7. Equipment Upgradation done like, Introduction of specific centering bush for oxygen-sensitive products at line-2, New Rubber stopper bowl, Replacement of Mobile LAF etc.;

8. Process Improvements done like Standardization of peristaltic pump RPM, Glove integrity testing after each batch, introduction of higher thickness neoprene cRAB gloves, introduction of Silicon saturated sterile wipes, Change parts management process, loose dispensing of rubber stoppers etc.;

9. Operational excellence project like Back-to-back filling for Busulfan Injection 60mg/10ml, Carboplatin Injection 450mg/45mL & 600mg/60mL, Docetaxel Injection 80mg/4ml, Etoposide Injection 100mg/5ml, Cytarabine Injection 1000mg/10ml etc.;

10. All the instruments are integrated with eLIMS with electronic work sheet to have paperless Quality control Lab;

11. 99.9% Stability sample analysis completed within SOP timeline;

12. In Anti-infective project Lacosamide, Parecoxib analysis completed within time to support the filing. In CSP Azacytidine Launch batch method transfer and three batch analysis completed within stipulated timeline;

13. Successfully Variation Filings from NSP Facility for Caspofungin For Injection and Parecoxib For Injection;

14. ETP upgradation done w.r.t energy efficient pumps and overall aesthetics;

15. Full fledge implementation of CNG for boiler operations in utility area;

16. RO system optimization to save reject water;

17. Co2 Footprint reduction in utility;

18. New Mobile LAFs introduced in CYTO block line 2;

19. PMS upgradation at Line 2;

20. 10 new GIT introduced in CYTO block for 100% gloves verification & testing as per Annex-11;

21. Introduction of material shifting elevator at Warehouse;

22. Introduction of dock leveler at Warehouse unloading bay;

23. In 2024, Improved 11% Right First Time in batch release comparison to 2023;

24. In 2024 total 1958 number batches were released with 5% Additional volume vs 2023.

The Baddi and Kalyani plants of the Company received certification(s) from the below mentioned authorities:

Baddi Plant:

1. Russia (Ministry of the health of the Russian Federation): Certification issued in May 2024 with a validity up to April 2027, Russian authority audited the facility in April 2024.

2. ISO 50001: Certification issued in March 2025 and valid up to December 2025.

3. Peru (Ministry of Health DIGEMID): Certification issued in July 2024 and valid up to May 2028.

4. CDSCO: Certification issued in October 2024 and valid up to August 2026, Centre drug authority audited the facility in August 2024.

5. EMA: issued in April 2025 and certification valid up to November 2026, HLfGP authority audited the facility in February 2025.

Kalyani Plant:

1. CDSCO/WBDC: Drug License valid till February, 2029.

2. ISO 9001 Certification valid upto 22^nd April, 2028.

3. TGA: Received a Manufacturer Questionnaire and the site submitted the updated questionnaire and automated acknowledgement was received, follow-ups done in May, 2024 and November, 2024 for inspection plan (in June 2025 received the inspection plan for site i.e. on 21-22 August, 2025).

4. EDQM/AIFA (Italy): Documents request received from EDQM on 9^th April, 2024 and site provided the documents on 15^th April, 2024, no further updates received.

During the year, the company had following employee engagement events at:

Kalyani Plant:

1. Town hall meeting for employees;

2. Quality Week Celebration;

3. Safety Week Celebration;

4. "International Women Day" Celebration;

5. "World Environment Day" Celebration;

6. Organized Fire & Safety Week Awareness Campaign;

7. "International Yoga Day" Celebration;

8. Family Day Celebration;

9. Deepawali Celebration (Rangoli Competition/Ethnic Wear/Lucky Draw Competition);

10. Monthly Birthday Celebration - FTE & Contract Workmen;

11. Independence Day celebration;

12. Coffee with Site Head;

13. Training on COC by Corporate Legal team;

14. Training on "Speak up Policy";

15. Training on "Engage, Empower & Transform";

16. Conducted an employee satisfaction survey.

Baddi Plant:

1. Celebration of "FKOL-PU Baddi Cricket Premier League " (for Male & Female employees)

2. Safety Week Celebration;

3. Annual Day Celebration;

4. Monthly Birthday Celebration;

5. International Womens Day Celebration;

6. Environment Day Celebration;

7. Knowledge Sharing Session;

8. Skip Level Meeting with Site Head;

9. Indoor Sports Celebration;

10. Townhall meetings for employees;

11. Coffee with senior leadership team (SLT) organized for employees;

12. Health Awareness Session on the occasion of World No Tobacco Day;

13. Health Awareness Session on the occasion of World Heart Day;

14. Yoga Day Celebration;

15. Blood Donation Camp;

16. Outbound Training Program - "Happitude";

17. Independence Day Celebration;

18. Holi Celebration;

19. Diwali Celebration;

20. Dusshera Celebration;

21. Christmas Celebration;

22. Quality Week Celebration;

23. Reward & Recognition- Star Performer, Quarter Best Employee, Long Service Award;

24. Conducted Employee Satisfaction Survey;

25. Workshop on Fresenius Principles;

26. Training on COC by Corporate Legal team;

27. Training on "Speak up Policy";

28. Vishwakarma Pooja.

Gurugram Office:

1. Holi Celebration;

2. Womens Day Celebration;

3. Yoga Day Celebration;

4. Quality Week Celebration;

5. Monthly Birthday Celebrations;

6. Independence Day Celebration;

7. Foundation Day Celebration;

8. Deepawali Celebration (Rangoli Competition/Ethnic Wear/Lucky Draw Competition);

9. Christmas Celebration;

10. Training for Internal Committee Members on "Prevention of Sexual Harassment";

11. Training for Jr. Management and Middle Management of OH and I&D - "The Power of 5 C";

12. Training for Jr. Management and Middle Management of OH and I&D - "Communication Skills"

13. Training Program for Jr. Management and Middle Management of OH - "Thriving in a VUCA World with VISION 26";

14. Training Program for Middle Management of I&D-Formulation - "Managers Bootcamp";

15. Training Program for Functional Heads and Team Leaders of I&D-Formulation-"Intentional Leadership";

16. Training Program for Functional Heads and Team Leaders of I&D-API-"In Pursuit of Excellence";

17. Training Program for all employees - "Fresenius Principles".

INITIATIVES TAKEN TO INCREASE EXPORTS; DEVELOPMENT OF NEW EXPORT MARKETS FOR PRODUCTS AND EXPORT PLANS:

The Company continues to play a lead role in the generic oncology space. Key strategic elements of this leadership strategy include portfolio expansion with new product developments, product differentiation, and strengthening the oncology portfolio pipeline across key export markets. All of these with the focus to provide healthcare professionals & patients high quality and cost-effective generic oncology drugs.

Speed to market, together with cost competitiveness remains one of our key objectives. Both are achieved by strong project coordination, helping us to cut down the time to launch new products (leveraging the first-mover advantage) and by our vertical integration of API and finished product.

Experience gained in generic Oncology drug manufacturing & marketing gives us the competitive advantage for some of the core cytotoxics that are used worldwide.

In FY 2024-25, the company received the market approvals for its products across the length and breadth of multiple geographies, ranging from Latin American markets to EU, the Middle East and the Asia Pacific, thus fortifying our market presence both in developed as well as key emerging markets.

Regulatory approvals during the period of our specialty injectable products such as Azacitidine, Bendamustine, Busulfan, Oxaliplatin, plus regulatory filings in as many as twenty-two markets across the globe testify our focus on product segments as well as market reach. We are confident of expanding our market presence & strengthening our market position via newer, cost competitive and differentiated products and serving more geographic regions.

As part of marketing activities to enhance the Companys image among the international societies, and spread product awareness, Fresenius Kabi took active part in various international conferences and scientific meetings relevant to the key therapeutic areas such as Oncology, Anaesthesia and Anti-infectives. Some of these knowledge forums among many is the prestigious EAHP conference (European Association of Hospital Pharmacists), during which we exhibited our wide range of generic Oncology injectable portfolio along with other product offerings from other therapeutic areas.

To conclude, we strongly believe that our continued focus on the new product development and other efforts as enumerated above will help us in increasing our export earnings in the future.

SHARE CAPITAL

During the year under review, there is no change in the share capital of the Company.

BOARD OF DIRECTORS

During the year under review, there is no change in the Board of Directors of the Company.

DIRECTORS RETIRING BY ROTATION

Dr. Marc-Alexander Mahl f DIN - 102798431

In terms of provisions of Section 152 of the Act, Dr. Marc-Alexander Mahl, Non-Executive Director and Chairman of the Board, would retire by rotation at the forthcoming Annual General Meeting and being eligible, offers himself for reappointment.

Dr. Mahl has been associated with the Company since August, 2023. The Board of Directors recommended his re-appointment.

Mr. Maximilian Alexander Boehmer ( DIN - 10279854)

In terms of provisions of Section 152 of the Act, Mr. Maximilian Alexander Boehmer, Non- Executive Director of the Company, would retire by rotation at the forthcoming Annual General Meeting and being eligible, offers himself for reappointment.

Mr. Boehmer has been associated with the Company since August, 2023. The Board of Directors recommended his re-appointment.

Kev Manaaerial Personnel (KMP)

During the year under review, there is no change in the Key Managerial Personnel.

STATUTORY AUDITORS

As per Section 139 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, the members of the company at their 19^th Annual General Meeting held on 25^th August, 2022 approved the appointment of M/s VMT & Co. LLP, Chartered Accountants (ICAI Registration No. - N500048), as the Statutory Auditors of the Company for the second term of 5 year i.e. from the conclusion of 19^th Annual General Meeting till the conclusion of the 24^th Annual General Meeting of the Company.

AUDITORS REPORT

The Board has duly examined the Statutory Auditors report and clarifications, wherever necessary, have been included in the notes to accounts section of the Annual Report.

The Report given by M/s VMT & Co. LLP, Chartered Accountants on the financial statements of the Company for the financial year 2024-25 is part of the Annual Report. There has been no qualification, reservation or adverse remark or disclaimer in their report.

During the year under review, the Auditors had not reported any matter under Section 143 (12) of the act, therefore, no detail is required to be disclosed under Section 134 (3) (ca) of the Act.

COMPLIANCE OF SECRETARIAL STANDARDS

The Company has complied with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India ("ICSI") during the year under review.

FIXED DEPOSITS

The Company has not invited/ accepted any Fixed Deposits during the year under review. Consequently, no amount of principal or interest on fixed deposits was outstanding on the Balance Sheet date.

COMMITTEES OF THE BOARD

In terms of the provisions of the Companies Act, 2013, read with rules made thereunder, the Company has constituted the following Committees:

a) Audit Committee

In terms of the provisions of Section 177 and other applicable provisions of the Companies Act, 2013, read with rules made thereunder, the Company has constituted an Audit Committee of Directors.

The composition of the Audit Committee during the FY 2024-25 is given below:

Member Director	Category	Status
Dr. Uday Chandrashekhar Shetty	Non-Executive (Independent)	Chairman
Dr. Marc-Alexander Mahl	Non-Executive	Member
Mr. Maximilian Alexander Boehmer	Non-Executive	Member

The role and terms of reference of the Audit Committee covers the areas mentioned in Section 177 of the Companies Act, 2013, besides other matters as may be referred by the Board of Directors.

b) Nomination and Remuneration Committee:

In terms of the provisions of Section 178 and other applicable provisions of the Companies Act, 2013, read with rules made thereunder, the Company has constituted a Nomination and Remuneration Committee of Directors.

The composition of the Nomination and Remuneration Committee during FY 2024-25 is given below:

Member Director	Category	Status
Dr. Uday Chandrashekhar Shetty	Non-Executive (Independent)	Chairman
Dr. Marc-Alexander Mahl	Non-Executive	Member
Mr. Maximilian Alexander Boehmer	Non-Executive	Member

The role and terms of reference of the Nomination and Remuneration Committee cover the areas mentioned in Section 178 of the Companies Act, 2013, besides other matters as may be referred by the Board of Directors.

The Committee has also adopted and implemented a policy named "Appointment, Remuneration and Evaluation Policy" for Directors, Key Managerial Personnel (KMPs) and Sr. Management Personnel in terms of the requirements of Section 178 of the Companies Act, 2013. A copy of the policy is attached as Annexure - I of this report.

c) Corporate Social Responsibility (CSR) Committee

In terms of the provisions of Section 135 and other applicable provisions of the Companies Act, 2013, read with rules made thereunder, the Company has constituted a CSR Committee.

The composition of the CSR Committee during FY 2024-25 is given below:

Member Director	Category	Status
Dr. Marc-Alexander Mahl	Non-Executive	Chairman
Mr. Arvind Kumar Sharma	Managing Director	Member
Dr. Uday Chandrashekhar Shetty	Non-Executive (Independent)	Member

The content of the CSR policy along with the update of CSR projects undertaken and statement of expenses incurred during the FY 2024-25 thereon is provided as Annexure - II of this report.

SECRETARIAL AUDIT

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and "The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014", the Company had appointed M/s Kiran Sharma & Co., a firm of Company Secretaries in Practice as "Secretarial Auditors" to undertake the Secretarial Audit of the Company for the financial year 2024-25. The
Secretarial Auditors have successfully carried out and completed the Secretarial Audit of the
Company for the FY 2024-25.

The Secretarial Audit Report is annexed as Annexure - III of this report and it does not contain
any qualification, reservation or adverse remark or disclaimer in their report.

COST AUDIT

In terms of the exemption granted under the provisions of the Companies Act, 2013, read with
Companies (Cost Records and Audit) Rules 2014, as amended from time to time, the Company is
not required to get its cost records audited by the Cost Auditors. Accordingly, the Cost records of
the Company for FY 2024-25, have not been audited by the Cost Auditors.

VIGIL MECHANISM

In terms of the requirements of the Companies Act, 2013, a Vigil Mechanism has been established
by the Company under the supervision of the Audit Committee of the Company. A dedicated
process and reporting mechanism have been devised under the Vigil Mechanism Policy, formulated
and implemented for this purpose.

For prompt and judicious redressal of the grievances/ complaints of the employees and Directors
of the Company, a nodal officer has also been designated for acting as a link between the Audit
Committee and the complainant(s).

Under this policy, the Nodal Officer is also required to:

s Provide a quarterly update about the grievances/ complaints received from employees and/or
Directors of the Company and the status of redressal thereof; and
V Ensure access of the Audit Committee Chairman to the concerned employee/ Director of the
Company in exceptional cases.

During the financial year 2024-25, no complaint was received pursuant to the vigil mechanism
policy.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE
(PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

We have zero tolerance towards sexual harassment and any act of sexual harassment, is dealt
with seriously and invites serious disciplinary action. In line with this, the Company has formulated
a Prevention of Sexual Harassment Policy. Pursuant to terms of this policy, employees can report
instances of sexual harassment at the workplace.

The Company has constituted Internal Complaints Committee (ICC) at its office, which is being
headed by a woman, to redress complaint(s) under the act, if any. The process is governed and
supported by the Prevention of Sexual Harassment Policy which ensures a free and fair enquiry
process.

Details of complaints received during the financial year ending on March 31, 2025, pertaining to
sexual harassment at workplace:

Sr. No. Particulars	No. of complaints
a Number of complaints of sexual harassment received in the year	NIL
b Number of complaints disposed off during the year	NA
c Number of cases pending for more than ninety days	NA

DISCLOSURE UNDER THE MATERNITY BENEFIT ACT, 1961

The Company is committed to supporting women employees and ensuring a safe and inclusive workplace. The Company has duly complied with the provisions of the Maternity Benefits Act, 1961 and rules made thereunder.

GENERAL BODY MEETINGS

The last three Annual General Meetings were held as under:

Financial Year	Location	Date	Time
2021 - 22	B-310, Som Datt Chambers-I, Bhikaji Cama Place, New Delhi - 110066	August 25, 2022	10:30 A.M.
2022 - 23	B-310, Som Datt Chambers-I, Bhikaji Cama Place, New Delhi - 110066	August 29, 2023	09:30 A.M.
2023 - 24	B-310, Som Datt Chambers-I, Bhikaji Cama Place, New Delhi - 110066	August 27, 2024	10:00 A.M.

The Twenty Second Annual General Meeting of the Company shall be held on Wednesday, August 20, 2025 at 10:30 A.M. at the Registered Office of the Company, B-310, Som Datt Chambers-I, Bhikaji Cama Place, New Delhi - 110066.

The members are requested to refer to the Notice of the Twenty Second Annual General Meeting for the detailed agenda and program.

REGISTRAR AND TRANSFER AGENT (RTA):

The details of RTA are given below:

For any query relating to the shares of the Company:- MUFG Intime India Private Limited (Formerly Link Intime India Private Limited)

Registrar and Share Transfer Agent,

Noble Heights, 1^st floor, Plot NH 2, C-l Block LSC,

Near Savitri Market, Janakpuri, New Delhi - 110058

Tel No.: +91 11 41410592/93/94 Fax: +91 11 41410591

E-mail: delhi@>in.moms,mufa.com 1 Website : www.in.rnDms.mufa.com

ADDRESS FOR CORRESPONDENCE:

For queries of Analysts, Fils, Institutions, Mutual Funds, Banks and Investors assistance:-

Mr. Nikhil Kulshreshtha,

Director & Secretary Fresenius Kabi Oncology Limited,

Echelon Institutional Area, Plot No - 11, Sector - 32,

Gurugram-122001, Haryana, India, Tel No. +91 124 488 5000 E-mail: corDoratesecretarial.india@fresenius-kabi.com Website : www.fresenius-kabi-oncoloqy.com

TRANSFER OF UNPAID DIVIDEND TO IEPF (Investor Education and Protection Fund)

In terms of Section 125 of the Companies Act, 2013, read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2015, during the year ended March 31, 2025, no amount is transferred to IEPF Authorities Bank Account.

DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to the requirements of Section 134 (3) (c) of the Companies Act, 2013, it is hereby confirmed that:

(a) in the preparation of annual accounts, the applicable accounting standards have been followed;

(b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for that period;

(c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

(d) the Directors have prepared the annual accounts on a going concern basis; and

(e) the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

ANNEXURES TO THE DIRECTORS REPORT

In terms of the requirements of Section 134(3) of the Companies Act, 2013, following documents/ information have also been annexed to the Directors Report:

1. In terms of sub section (1) of Section 178 of the Companies Act, 2013, Companys policy on Directors appointment and remuneration, including criteria for determining qualifications, positive attributes, independence of Directors and other matters provided under sub section (3) of Section 178 (Annexure - I),

2. The content of the CSR policy along with the update of CSR projects undertaken and statement of expenses incurred during the FY 2024-25 (Annexure - II),

3. Secretarial Audit Report for FY 2024-25 (Annexure - III),

4. No. of Meetings of the Board of Directors held during the year (Annexure -IV),

5. Statement on declaration given by the Independent Director under sub section (5) of Section 149 (Annexure - V),

6. Particulars of loans, guarantees or investments under Section 186: No such transaction during the year,

7. Particulars of contracts or arrangements with related parties referred to in sub section (1) of Section 188: All Related Party Transactions that were entered into during the financial year were in the ordinary course of the business and on arms length basis, details of which are mentioned in the Notes to Accounts forming part of the financial statements. All such transactions/ contracts/ arrangements with related parties were in compliance with the provisions of Section 188 of the Companies Act, 2013.

There were no materially significant related party transactions entered by the Company with Directors, Key Managerial Personnel or other persons which may have a potential conflict with the interest of the Company.

8. Conservation of energy, technology absorption and foreign exchange earnings and outgo (Annexure - VI),

9. A statement indicating development and implementation of a risk management policy for the Company including identification therein of elements of risk, if any, which in the opinion of theBoard may threaten the existence of the Company (Annexure - VII),

10. The details in respect of adequacy of internal financial controls with reference to the Financial Statements. (Annexure - VIII),

11. Extract of the Annual Return as provided under sub section (3) of Section 92 (Annexure - IX),

ACKNOWLEDGEMENT / APPRECIATION

The Directors wish to place on record their appreciation for the Companys customers, vendors,
investors and bankers for their continued support during the year. The Directors also thank the
employees for the efficient contribution made by them at all levels. Our consistent growth has
been made possible by their whole-hearted efforts, solidarity, co-operation and support.

The Directors also thank the Government of India, particularly the Ministry of Corporate Affairs,
Department of Pharmaceuticals, the GST departments, the Income Tax Department, the Ministry
of Commerce, the Ministry of Finance, the Reserve Bank of India and other Government agencies
for their support and look forward to their continued support in the future.

For and on behalf of the Board of Directors

Place: Gurugram	Marc-Alexander Mahl
July 25, 2025	1 Chairman
	DIN - 10279843